LiveLung的动态

We look forward to Dr. Denang Li’s presentation of the final data from our Phase 2 combination study of casdozo with standard of care in patients with liver cancer on Friday at the 2025 American Society of Clinical Oncology (ASCO) GI Symposium. Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate the durability of response and improvement in the depth of response, including a 17.2% complete response rate. Read more about the data and the upcoming presentation in our press release: https://bit.ly/3PL5myo

Exciting #Portfolio Update: Feminai has reached a major milestone by completing its first-in-human clinical trial on 100 patients at Sheba Medical Center, Tel Hashomer, achieving 96% sensitivity and 98% negative predictive value (NPV), demonstrating remarkable accuracy in non-invasive breast cancer detection. We’re excited to support their continued progress! Guy Katsovich | Yair Vardi | Amit Shechter

Medical knowledge is literally doubling every 60 days. There is no one person alive that can retain, recall, and instantly apply the collective wisdom of all of our advancements. ?? Your oncologist is perhaps the MOST amazing human you’ve ever met - but only human. ?? That’s why we are building Tailwind. We bring the collective wisdom of the top 1% oncology research at everyones fingertips. ?? Cancer can be beaten - but it requires for all of our wisdom to come together. ?? Come ask your most complex query. Try Tailwind for free https://lnkd.in/ezWS68A5 ?? Full version is by invitation only. If you are an oncologist, send us a DM for a non-commercial trial.

??Only Two Weeks Left to Register!?? Join us for the 25th Advances in Oncology Conference on November 15-16, 2024! Review?key agenda highlights and gain insights from leading medical experts. Topics include:? ? Malignant Hematology Panel Discussion? ? Breast Cancer Panel Discussion? ? Updates on Sickle Cell Anemia & Hemoglobinopathies? …and much more! Don't miss out—register now at advancesinoncology.net! ?? #OncologyConference #MedicalInsights #RegisterNow

We are excited to share that ClinicalPath, Elsevier’s oncology decision support solution, is showcased in today’s Cancer Moonshot Fact Sheet released by The White House. ClinicalPath plans to launch new capabilities prompting oncologists to incorporate precision medicine into their treatment decision making – this will help to ensure cancer patients have access to innovative precision medicine treatment, including the latest clinical trials. We’re proud to see ClinicalPath featured in this important initiative and look forward to seeing how it supports oncologists at the point of care. Explore the fact sheet here: https://lnkd.in/eAmg33w5 #ClinicalPath #CancerMoonshot #PrecisionMedicine

Very cool to see the product I lead design on for the past few years be recognized on such a large scale. Last year I was tasked with coming up with a concept to envision the future of ClinicalPath. The features being highlighted by The Biden Cancer Moonshot as essential for making progress against cancer were part of that vision. They are: 1. Accessing and utilizing a patient's biomarker data at the point of care to aid in precision care and offering the best treatment options 2. Giving providers access to view and select local, relevant clinical trials as part of a treatment plan 3. An overall better user experience that takes away the administrative burden and allows providers to engage in the more human parts of cancer care. This recognition is a testament to the essential need of UX Designers and Researchers in the medical tech space. We spent hours interviewing, gathering needs and frustrations and analyzing data to understand how we might be able to better serve providers so that patient's get the best possible outcomes while navigating their care. And none of the work we do as Designers is possible without the collaboration of the Product Managers and Commercial team who connect us to providers, know the ins and outs of the product and cooperate with us when we want to do a million workshops ?? Cheers to the whole CP team ??

Addressing a full audience at the 11th annual Clinical Trials in Oncology conference in Munich, vice president of patient engagement for Medidata Dassault Systems, Alicia Staley shared her personal cancer treatment journey. She highlighted how assumptions, inadequate record keeping, or insufficient information can hinder trial progress and deter patients from participating in potentially lifesaving clinical trials. https://gag.gl/DbqapN

Speaking to a packed room at the 11th annual Clinical Trials in Oncology conference in Munich, vice president of patient engagement for Medidata Dassault Systems, Alicia Staley detailed her personal cancer treatment journey, and how assumptions, poor record keeping, or a lack of viable information can stand in the way of trial progress and push patients away from potentially lifesaving clinical trials. https://gag.gl/DbqapN

Speaking to a packed room at the 11th annual Clinical Trials in Oncology conference in Munich, vice president of patient engagement for Medidata Dassault Systems, Alicia Staley detailed her personal cancer treatment journey, and how assumptions, poor record keeping, or a lack of viable information can stand in the way of trial progress and push patients away from potentially lifesaving clinical trials. https://gag.gl/DbqapN

Speaking to a packed room at the 11th annual Clinical Trials in Oncology conference in Munich, vice president of patient engagement for Medidata Dassault Systems, Alicia Staley detailed her personal cancer treatment journey, and how assumptions, poor record keeping, or a lack of viable information can stand in the way of trial progress and push patients away from potentially lifesaving clinical trials. https://gag.gl/DbqapN